As per June 30, 2011, the total number of shares in Vitrolife AB (publ) amounts to 19,562,769, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 19,954,024.38.
At the beginning of the month the total number of shares in the company amounted to 19,559,857, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 19,951,054.14.
The increase in the number of shares by 2,912 during the month of June is due to the exercising of options to subscribe for new shares under Vitrolife’s warrants program 2008/2011, which ended on May 31, 2011.
Gothenburg, June 30, 2011
Vitrolife AB (publ)
Queries should be addressed to:
Anne-Lie Sveder, CFO, phone +46 31 721 80 13
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: email@example.com. Website: www.vitrolife.com.
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and the Swedish Financial Instruments Trading Act. The information was submitted for publication on Thursday June 30, 2011, at 08:30 CET.